Victoria Moreno-Manzano

Dr. Victoria Moreno-Manzano

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 May 2022 in Nature Communications
Verified
Journal Article
Open access
PDF file
IFIsaac Francos-Quijorna
Isaac Francos-Quijorna
MSMarina Sánchez-Petidier
Marina Sánchez-Petidier
EBEmily R. Burnside
Emily R. Burnside
SBSmaranda R. Badea
Smaranda R. Badea
ATAbel Torres-Espin
Abel Torres-Espin
EBElizabeth J. Bradbury
Elizabeth J. Bradbury
Chondroitin sulfate proteoglycans (CSPGs) act as potent inhibitors of axonal growth and neuroplasticity after spinal cord injury (SCI). Here we reveal that CSPGs also play a critical role in preventing inflammation resolution by blocking the conversion of pro-inflammatory immune cells to a pro-repair phenotype in rodent models of SCI. We demonstrate that enzymatic digestion of CSPG glycosaminoglycans enhances immune cell clearance and reduces pro-inflammatory protein and gene expression profiles at key resolution time points. Analysis of phenotypically distinct immune cell clusters revealed CSPG-mediated modulation of macrophage and microglial subtypes which, together with T lymphocyte infiltration and composition changes, suggests a role for CSPGs in modulating both innate and adaptive immune responses after SCI. Mechanistically, CSPG activation of a pro-inflammatory phenotype in pro-repair immune cells was found to be TLR4-dependent, identifying TLR4 signalling as a key driver of CSPG-mediated immune modulation. These findings establish CSPGs as critical mediators of inflammation resolution failure after SCI in rodents, which leads to prolonged inflammatory pathology and irreversible tissue destruction.

1 January 2020 in International Journal of Biological Macromolecules
Verified
Journal Article
Closed access
ARAriagna L. Rivera-Briso
Ariagna L. Rivera-Briso
FAFinn Lillelund Aachmann
Finn Lillelund Aachmann
VMVictoria Moreno-Manzano
Victoria Moreno-Manzano
Ángel Serrano-ArocaÁngel Serrano-Aroca
Ángel Serrano-Aroca

Verified
Journal Article
Open access
PDF file
Ángel Serrano-ArocaÁngel Serrano-Aroca
Ángel Serrano-Aroca
CVCesar David Vera-Donoso
Cesar David Vera-Donoso
VMVictoria Moreno-Manzano
Victoria Moreno-Manzano
Current clinical strategies for bladder reconstruction or substitution are associated to serious problems. Therefore, new alternative approaches are becoming more and more necessary. The purpose of this work is to review the state of the art of the current bioengineering advances and obstacles reported in bladder regeneration. Tissue bladder engineering requires an ideal engineered bladder scaffold composed of a biocompatible material suitable to sustain the mechanical forces necessary for bladder filling and emptying. In addition, an engineered bladder needs to reconstruct a compliant muscular wall and a highly specialized urothelium, well-orchestrated under control of autonomic and sensory innervations. Bioreactors play a very important role allowing cell growth and specialization into a tissue-engineered vascular construct within a physiological environment. Bioprinting technology is rapidly progressing, achieving the generation of custom-made structural supports using an increasing number of different polymers as ink with a high capacity of reproducibility. Although many promising results have been achieved, few of them have been tested with clinical success. This lack of satisfactory applications is a good reason to discourage researchers in this field and explains, somehow, the limited high-impact scientific production in this area during the last decade, emphasizing that still much more progress is required before bioengineered bladders become a commonplace in the clinical setting.

1 January 2017 in Biomaterials
Verified
Journal Article
Closed access
RRRaquel Requejo-Aguilar
Raquel Requejo-Aguilar
AAAna Alastrue-Agudo
Ana Alastrue-Agudo
MCMarta Cases-Villar
Marta Cases-Villar
ELEric Lopez-Mocholi
Eric Lopez-Mocholi
RERichard England
Richard England
VMVictoria Moreno-Manzano
Victoria Moreno-Manzano

Verified
Journal Article
Open access
PDF file
PBPablo Bonilla
Pablo Bonilla
JHJoaquim Hernandez
Joaquim Hernandez
EGEsther Giraldo
Esther Giraldo
MGMiguel A. González-Pérez
Miguel A. González-Pérez
AAAna Alastrué
Ana Alastrué
VMVictoria Moreno-Manzano
Victoria Moreno-Manzano
We currently lack effective treatments for the devastating loss of neural function associated with spinal cord injury (SCI). In this study, we evaluated a combination therapy comprising human neural stem cells derived from induced pluripotent stem cells (iPSC-NSC), human mesenchymal stem cells (MSC), and a pH-responsive polyacetal–curcumin nanoconjugate (PA-C) that allows the sustained release of curcumin. In vitro analysis demonstrated that PA-C treatment protected iPSC-NSC from oxidative damage in vitro, while MSC co-culture prevented lipopolysaccharide-induced activation of nuclear factor-κB (NF-κB) in iPSC-NSC. Then, we evaluated the combination of PA-C delivery into the intrathecal space in a rat model of contusive SCI with stem cell transplantation. While we failed to observe significant improvements in locomotor function (BBB scale) in treated animals, histological analysis revealed that PA-C-treated or PA-C and iPSC-NSC + MSC-treated animals displayed significantly smaller scars, while PA-C and iPSC-NSC + MSC treatment induced the preservation of β-III Tubulin-positive axons. iPSC-NSC + MSC transplantation fostered the preservation of motoneurons and myelinated tracts, while PA-C treatment polarized microglia into an anti-inflammatory phenotype. Overall, the combination of stem cell transplantation and PA-C treatment confers higher neuroprotective effects compared to individual treatments.

1 January 2017 in Stem Cells International
Verified
Journal Article
Open access
PDF file
IMIgnacio Muñoz-Criado
Ignacio Muñoz-Criado
JMJose Meseguer-Ripolles
Jose Meseguer-Ripolles
MMMaravillas Mellado-López
Maravillas Mellado-López
AAAna Alastrue-Agudo
Ana Alastrue-Agudo
RGRichard J Griffeth
Richard J Griffeth
VMVictoria Moreno-Manzano
Victoria Moreno-Manzano
Cartilage degeneration is associated with degenerative bone and joint processes in severe osteoarthritis (OA). Spontaneous cartilage regeneration is extremely limited. Often the treatment consists of a partial or complete joint implant. Adipose-derived stem cell (ASC) transplantation has been shown to restore degenerated cartilage; however, regenerative differences of ASC would depend on the source of adipose tissue. The infra- and suprapatellar fat pads surrounding the knee offer a potential autologous source of ASC for patients after complete joint substitution. When infrapatellar- and suprapatellar-derived stromal vascular fractions (SVF) were compared, a significantly higher CD105 (+) population was found in the suprapatellar fat. In addition, the suprapatellar SVF exhibited increased numbers of colony formation units and a higher population doubling in culture compared to the infrapatellar fraction. Both the suprapatellar- and infrapatellar-derived ASC were differentiated in vitro into mature adipocytes, osteocytes, and chondrocytes. However, the suprapatellar-derived ASC showed higher osteogenic and chondrogenic efficiency. Suprapatellar-derived ASC transplantation in a severe OA mouse model significantly diminished the OA-associated knee inflammation and cartilage degenerative grade, significantly increasing the production of glycosaminoglycan and inducing endogenous chondrogenesis in comparison with the control group. Overall, suprapatellar-derived ASC offer a potential autologous regenerative treatment for patients with multiple degenerative OA.